Submitted:
17 July 2023
Posted:
18 July 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Ethics Approval
2.3. Inclusion and Exclusion Criteria
2.4. Statistical Analysis
3. Results
4. Discussion
4.1. Strengths and Weaknesses (Study Limitations)
4.2. Further Research
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009;169(9):894-900. [CrossRef]
- Hohl CM, Partovi N, Ghement I, et al. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS One. 2017;12(2):e0170495. Published 2017 Feb 13. [CrossRef]
- Nguyen AD, Lam A, Banakh I, Lam S, Crofts T. Improved Medication Management With Introduction of a Perioperative and Prescribing Pharmacist Service. J Pharm Pract. 2020;33(3):299-305. [CrossRef]
- Italian Ministry of Health, Recommendation No. 17 - Reconciliation of drug therapy. December 2014 (Ministero della Salute, Raccomandazione n. 17 - Riconciliazione della terapia farmacologica. Dicembre 2014), https://www.salute.gov.it/imgs/C_17_pubblicazioni_2354_allegato.pdf.
- Chiarelli MT, Antoniazzi S, Cortesi L, et al. Pharmacist-driven medication recognition/ reconciliation in older medical patients. Eur J Intern Med. 2021;83:39-44. [CrossRef]
- Kennedy JM, van Rij AM, Spears GF, Pettigrew RA, Tucker IG. Polypharmacy in a general surgical unit and consequences of drug withdrawal. Br J Clin Pharmacol. 2000;49(4):353-362. [CrossRef]
- von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-1499. [CrossRef]
- Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-191. [CrossRef]
- R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
- Wireko AA, Ohenewaa Tenkorang P, Tope Adebusoye F, et al. The importance of pharmacists in modern day surgery - editorial. Int J Surg. 2023;109(2):88-90. Published 2023 Feb 1. [CrossRef]
- Abdulghani KH, Aseeri MA, Mahmoud A, Abulezz R. The impact of pharmacist-led medication reconciliation during admission at tertiary care hospital. Int J Clin Pharm. 2018;40(1):196-201. [CrossRef]
- van den Bemt PM, van der Schrieck-de Loos EM, van der Linden C, Theeuwes AM, Pol AG; Dutch CBO WHO High 5s Study Group. Effect of medication reconciliation on unintentional medication discrepancies in acute hospital admissions of elderly adults: a multicenter study. J Am Geriatr Soc. 2013;61(8):1262-1268. [CrossRef]
- Nanji KC, Patel A, Shaikh S, Seger DL, Bates DW. Evaluation of Perioperative Medication Errors and Adverse Drug Events. Anesthesiology. 2016;124(1):25-34. [CrossRef]
- Renaudin A, Leguelinel-Blache G, Choukroun C, et al. (2020) Impact of a preoperative pharmaceutical consultation in scheduled orthopedic surgery on admission: a prospective observational study. BMC Health Serv Res. 2020 Aug 13;20(1):747. [CrossRef] [PubMed] [PubMed Central]
- Vallecillo T, Slimano F, Moussouni M, et al. (2022) Development and validation of a ready-to-use score to prioritise medication reconciliation at patient admission in an orthopaedic and trauma department. Eur J Hosp Pharm. 2022 Sep;29(5):264-270. Epub 2020 Dec 8. [CrossRef] [PubMed] [PubMed Central]
- Cheng HT, Zhao M, Liu HT, Shen GL, Zhao T, Feng ZE (2022) The prevalence of chronic medication therapy problems and pharmacists' interventions among hospitalized perioperative patients: a retrospective observational study. BMC Health Serv Res. 2022 Dec 6;22(1):1483. [CrossRef] [PubMed] [PubMed Central]
- Patel GP, Hyland SJ, Birrer KL, et al. (2020) Perioperative clinical pharmacy practice: Responsibilities and scope within the surgical care continuum. JACCP Journal of the American College of Clinical Pharmacy, 3(2), 501-519. [CrossRef]
- Lovely JK, Hyland SJ, Smith AN, Nelson G, Ljungqvist O, Parrish RH 2nd. Clinical pharmacist perspectives for optimizing pharmacotherapy within Enhanced Recovery After Surgery (ERAS®) programs. Int J Surg. 2019;63:58-62. [CrossRef]
- Khalil V, deClifford JM, Lam S, Subramaniam A (2016) Implementation and evaluation of a collaborative clinical pharmacist's medications reconciliation and charting service for admitted medical inpatients in a metropolitan hospital. J Clin Pharm Ther. 2016 Dec;41(6):662-666. Epub 2016 Aug 31. [CrossRef] [PubMed]
- deClifford JM, Lam SH, Leung BK (2009) Evaluation of a pharmacist-initiated e-prescription transcription service for discharged patients. J Pharm Pract Res, 2009;39 (1):33–36.
- deClifford JM, Caplygin FM, Lam SS and Leung BK (2007), Impact of an Emergency Department Pharmacist on Prescribing Errors in an Australian Hospital. Journal of Pharmacy Practice and Research, 37: 284-286. [CrossRef]
- Bond CA, Raehl CL, Franke T (2002) Clinical pharmacy services, hospital pharmacy staffing and medication errors in United States hospitals. Pharmacotherapy 2002; 22: 134-47.
- Hurria A, Browner IS, Cohen HJ, et al. (2012) Senior adult oncology. J Natl Compr Canc Netw. 2012 Feb;10(2):162-209. [CrossRef] [PubMed] [PubMed Central]
- Coutsouvelis J, Siderov J, Tey A, et al. (2020) The impact of pharmacist-led strategies implemented to reduce errors related to cancer therapies: a systematic review. Journal of Pharmacy Practice and Research, 50.
- Neville HL, Chevalier B, Daley C, et al. Clinical benefits and economic impact of post-surgical care provided by pharmacists in a Canadian hospital. Int J Pharm Pract. 2014;22(3):216-222. [CrossRef]

| Variables | All patients (N=140) |
Control Group (N=70) |
Intervention Group (N=70) |
p |
|---|---|---|---|---|
| Male, n (%) | 75 (53.6) | 37 (52.8) | 38 (54.3) | 0.862 |
| Age, median (IQR) | 61 (55-73) | 60 (55-74) | 64 (56-75) | 0.760 |
| Comorbidities, median (IQR) | 3 (2-5) | 3 (2.5-4) | 3 (2-5) | 0.804 |
| Patients aged ≥ 65 years (%) | 67 (47.8) | 34 (48.6) | 33 (47.1) | 0.863 |
| Polypharmacy, median (IQR) | 4(2-5) | 4(2-5) | 4(2.25-6) | 0.308 |
| Patients in polypharmacotherapy (drugs taken ≥3; %) | 96 (68.6) | 44 (62.8) | 52 (74.3) | 0.145 |
| Type of surgery | <0.05 | |||
| General surgery (%) | 73 (52.1) | 70 (100.0) | 3 (4.3) | -- |
| Gastric surgery (%) | 62 (44.8) | 0 (0.0) | 62 (88.6) | -- |
| Others (%) | 5 (3.1) | 0 (0.0) | 5 (7.1) | -- |
| Information reported in the BPMH | Control Group (N=70) |
Intervention Group (N=70) |
p |
|---|---|---|---|
| Active pharmaceutical ingredient (%) | 21 (30.0) | 68 (97.1) | <0.05 |
| Brand name (%) | 53 (75.7) | 69 (98.6) | <0.05 |
| Route of administration (%) | 44 (62.9) | 70 (100) | <0.05 |
| Pharmaceutical form (%) | 53 (75.7) | 70 (100) | <0.05 |
| Dosage (%) | 55 (78.6) | 68 (97.1) | <0.05 |
| Posology (%) | 49 (70.0) | 70 (100) | <0.05 |
| Date of drug initiation (%) | 0 (0.0) | 64 (91.4) | N.A. |
| Drug therapy duration (%) | 0 (0.0) | 67 (95.7) | N.A. |
| Need for a manipulated pharmaceutical form (%) | 0 (0.0) | 70 (100) | N.A. |
| Homeopathic/supplements/others (%) | 25 (35.7) | 70 (100) | <0.05 |
| Total omissions (%) | 400/700 (57.1) | 14/700 (2.0) | <0.05 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).